Noonan syndrome and Noonan-related syndrome: genes and variants
Explore variant evidence for Noonan syndrome and Noonan-related syndrome across 12 analyzed proteins (PTPN11, BRAF, SOS1, RIT1, RAF1 and 7 more). Linked ClinVar records include 70 pathogenic or likely pathogenic variants, 61 variants of uncertain significance and 36 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Noonan syndrome and Noonan-related syndrome
PTPN11: Tyrosine-protein phosphatase non-receptor type 11
Its SHP2 phosphatase activity promotes RAS-MAPK signaling downstream of many receptor tyrosine kinases and cytokine receptors. Germline dysregulating variants cause Noonan-spectrum disorders, while somatic activating variants drive juvenile myelomonocytic leukemia and other cancers.
29 ClinVar pathogenic / likely pathogenic and 9 uncertain variants in PTPN11 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
10 ClinVar pathogenic / likely pathogenic and 7 uncertain variants in BRAF have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
SOS1: Son of sevenless homolog 1
It activates RAS by exchanging GDP for GTP downstream of receptor tyrosine kinases. Germline activating variants are a common cause of Noonan syndrome, while excessive SOS1-RAS signaling can contribute to cancer.
9 ClinVar pathogenic / likely pathogenic and 20 uncertain variants in SOS1 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
RIT1: GTP-binding protein Rit1
It transmits growth and stress signals through RAS-MAPK and related pathways and is important in cardiovascular and nervous-system development. Germline activating variants cause Noonan syndrome, often with a high frequency of hypertrophic cardiomyopathy.
9 ClinVar pathogenic / likely pathogenic and 7 uncertain variants in RIT1 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
RAF1: RAF proto-oncogene serine/threonine-protein kinase
It relays activated RAS signals to MEK and ERK and also participates in survival and developmental pathways. Germline activating variants cause Noonan syndrome and related RASopathies, while oncogenic activation contributes to selected cancers.
4 ClinVar pathogenic / likely pathogenic and 11 uncertain variants in RAF1 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
HRAS: GTPase HRas
Its GTP-bound state activates RAF-MEK-ERK and other pathways downstream of growth-factor receptors. Somatic activating variants drive several cancers, while germline activating variants cause Costello syndrome.
3 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in HRAS have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
CBL: E3 ubiquitin-protein ligase CBL
It limits receptor-tyrosine-kinase signaling by ubiquitinating activated receptors and promoting their internalization and degradation. Germline or somatic pathogenic variants can prolong RAS-MAPK signaling and cause Noonan-like developmental disease or myeloid malignancy.
2 ClinVar pathogenic / likely pathogenic and 22 uncertain variants in CBL have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
2 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in NRAS have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
1 ClinVar pathogenic / likely pathogenic and 4 uncertain variants in MAP2K1 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
1 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in KRAS have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
SOS2: Son of sevenless homolog 2
It activates RAS by catalyzing GDP-GTP exchange downstream of growth-factor receptors. Germline activating variants cause Noonan syndrome, generally through increased RAS-MAPK signaling.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in SOS2 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
0 ClinVar pathogenic / likely pathogenic and 8 uncertain variants in MAP2K2 have source records linked to Noonan syndrome and Noonan-related syndrome. Association strength is not clinical gene validity.
Where Noonan syndrome and Noonan-related syndrome variants cluster
- PTPN11 SH2 1 (positions 6–102): 16 of 29 ClinVar pathogenic / likely pathogenic variants, 3.4× more than its size predicts (a length-based count, not a validated hotspot).
- BRAF Phorbol-ester/DAG-type (positions 234–280): 4 of 10 ClinVar pathogenic / likely pathogenic variants, 6.5× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Noonan syndrome and Noonan-related syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| SOS1 R552M | 552 | Pathogenic / likely pathogenic (★★★) | |
| SOS1 R552W | 552 | Pathogenic / likely pathogenic (★★★) | |
| SOS1 R552S | 552 | Pathogenic / likely pathogenic (★★★) | |
| PTPN11 I56V | 56 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| BRAF F247S | 247 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| BRAF F247V | 247 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| BRAF F247L | 247 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| PTPN11 I56T | 56 | SH2 1 | Pathogenic / likely pathogenic (★★★) |
| BRAF L245F | 245 | Phorbol-ester/DAG-type | Pathogenic / likely pathogenic (★★★) |
| SOS1 F623I | 623 | N-terminal Ras-GEF | Pathogenic / likely pathogenic (★★★) |
| SOS1 V171A | 171 | Pathogenic / likely pathogenic (★★★) | |
| PTPN11 G60A | 60 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 D61G | 61 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 A72S | 72 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 R498W | 498 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| HRAS G13D | 13 | Pathogenic / likely pathogenic (★★) | |
| HRAS G13R | 13 | Pathogenic / likely pathogenic (★★) | |
| NRAS G12D | 12 | Pathogenic / likely pathogenic (★★) | |
| NRAS G12A | 12 | Pathogenic / likely pathogenic (★★) | |
| PTPN11 D61N | 61 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 E76D | 76 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 P491L | 491 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| RIT1 F82V | 82 | Pathogenic / likely pathogenic (★★) | |
| RIT1 F82L | 82 | Pathogenic / likely pathogenic (★★) | |
| PTPN11 N58D | 58 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 N58K | 58 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 G60V | 60 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 A72T | 72 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 A72G | 72 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 E76V | 76 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 E76Q | 76 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 N308T | 308 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 P491S | 491 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 R498L | 498 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 G503R | 503 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| RAF1 P261T | 261 | Pathogenic / likely pathogenic (★★) | |
| RAF1 P261R | 261 | Pathogenic / likely pathogenic (★★) | |
| RIT1 Y89H | 89 | Pathogenic / likely pathogenic (★★) | |
| SOS1 G434R | 434 | Pathogenic / likely pathogenic (★★) | |
| HRAS G12D | 12 | Pathogenic / likely pathogenic (★★) | |
| KRAS G13D | 13 | Pathogenic / likely pathogenic (★★) | |
| PTPN11 N308S | 308 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 P491A | 491 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| RIT1 E81G | 81 | Pathogenic / likely pathogenic (★★) | |
| RIT1 D87H | 87 | Pathogenic / likely pathogenic (★★) | |
| RIT1 M90I | 90 | Pathogenic / likely pathogenic (★★) | |
| BRAF G464V | 464 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF F468S | 468 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF G469R | 469 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF K499E | 499 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| BRAF L597V | 597 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| PTPN11 T73I | 73 | SH2 1 | Pathogenic / likely pathogenic (★★) |
| PTPN11 I282V | 282 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 F285S | 285 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| PTPN11 T468P | 468 | Tyrosine-protein phosphatase | Pathogenic / likely pathogenic (★★) |
| RAF1 S259F | 259 | Pathogenic / likely pathogenic (★★) | |
| RIT1 G95A | 95 | Pathogenic / likely pathogenic (★★) | |
| SOS1 E433K | 433 | Pathogenic / likely pathogenic (★★) | |
| SOS1 I437T | 437 | Pathogenic / likely pathogenic (★★) | |
| CBL Q367P | 367 | Linker | Pathogenic / likely pathogenic (★★) |
Showing 60 of 70.
Which prediction tools work for Noonan syndrome and Noonan-related syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 97 out of 100
- REVEL: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 94 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 87 out of 100
- PolyPhen-2: 85 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CADD: 83 out of 100
- EVE: 78 out of 100
- SIFT: 74 out of 100
- phyloP: 71 out of 100
- Pangolin: 59 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SpliceAI: 48 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- RASopathy also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (51 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (44 pathogenic / likely pathogenic).
- LEOPARD syndrome also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (16 pathogenic / likely pathogenic).
- Metachondromatosis also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (11 pathogenic / likely pathogenic).
- Monogenic short statue also has ClinVar records linked to PTPN11 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (6 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (36 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (26 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (17 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (11 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to BRAF variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (9 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to SOS1 variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (30 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to SOS1 variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (22 pathogenic / likely pathogenic).
- Fibromatosis, gingival, 1 also has ClinVar records linked to SOS1 variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (4 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to RIT1 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (22 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to RIT1 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (5 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to RAF1 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (28 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to RAF1 variants; they fall in the same places as the Noonan syndrome and Noonan-related syndrome variants (14 pathogenic / likely pathogenic).
- Dilated cardiomyopathy 1NN also has ClinVar records linked to RAF1 variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (5 pathogenic / likely pathogenic).
- LEOPARD syndrome also has ClinVar records linked to RAF1 variants; they fall in the same places as the Noonan syndrome and Noonan-related syndrome variants (4 pathogenic / likely pathogenic).
- Costello syndrome also has ClinVar records linked to HRAS variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (15 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to HRAS variants; they fall mostly in different places as the Noonan syndrome and Noonan-related syndrome variants (6 pathogenic / likely pathogenic).
- Large congenital melanocytic nevus also has ClinVar records linked to HRAS variants; they fall partly in the same places as the Noonan syndrome and Noonan-related syndrome variants (5 pathogenic / likely pathogenic).
Diseases related to Noonan syndrome and Noonan-related syndrome
- RASopathy, also linked to BRAF, CBL, HRAS, KRAS and 8 more
- Noonan syndrome, also linked to BRAF, CBL, HRAS, KRAS and 8 more
- Hypertrophic cardiomyopathy, also linked to BRAF, HRAS, MAP2K1, MAP2K2 and 1 more
- Cardiofaciocutaneous syndrome, also linked to BRAF, KRAS, MAP2K1, MAP2K2 and 1 more
- Costello syndrome, also linked to BRAF, HRAS, MAP2K1, MAP2K2 and 1 more
- Cardio-facio-cutaneous syndrome, also linked to BRAF, KRAS, MAP2K1 and MAP2K2
- Vascular malformation, also linked to BRAF, KRAS, MAP2K1 and NRAS
- Myelomonocytic leukemia, also linked to CBL, KRAS, NRAS and PTPN11
- Melanoma, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Acute myeloid leukemia, also linked to KRAS, NRAS and PTPN11
- LEOPARD syndrome, also linked to BRAF, PTPN11 and RAF1
- Colorectal cancer, also linked to BRAF, KRAS and NRAS
Frequently asked questions
Which genes have records linked to Noonan syndrome and Noonan-related syndrome?
This view contains 12 analyzed proteins: PTPN11, BRAF, SOS1, RIT1, RAF1 and 7 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 70 pathogenic or likely pathogenic variants, 61 variants of uncertain significance and 36 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 213 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center